Instead, cardiovascular risk declines, particularly in patients with established atherosclerotic disease
Keep you powerful, strong, and active throughout the day
Wegovy remains covered for cardiovascular risk reduction and MASH liver disease under many plans
This can feel like hunger returning more quickly or regaining the ability to eat larger portions
For alcoholic hepatitis 1.8 g intravenously per day for 14-30 days in the form of infusions
Semaglutide Market Segmentation Analysis: By product, Ozempic held the largest share of around 60.94% in 2025, and the Wegovy segment is expected to register the highest growth By route of administration, the parenteral segment dominated the market with approximately 88.80%share in 2025, while the oral segment is expected to register the highest growth By application, type 2 diabetes mellitus accounted for the leading share of nearly 70.40% in 2025, and obesity is expected to register the highest growth Distribution channel, the retail pharmacies led the market with about 56.61% share in 2025, and online pharmacies are forecasted to grow the fastest By Product, Ozempic leads the Market, While Wegovy registers the Fastest Growth The Ozempic segment accounted for the highest revenue share of approximately 60.94% in 2025, owing to its established effectiveness in treating type 2 diabetes, its potential for reducing cardiovascular risk, and the convenience of a once-a-week dosing schedule
